Neratinib-Based Combination Strategies Could Be Effective in FLC
Investigators of the SUMMIT basket trial evaluated the efficacy of neratinib both as a monotherapy and in combination with other agents in patients with fibrolamellar carcinoma (FLC).
American Society of Clinical Oncology Gastrointestinal (ASCO GI) Symposium
Lenvatinib Plus Pembrolizumab Safe, Effective in non-MSI-H/pMMR CRC
LEAP-005 investigators tested the safety and efficacy of combination lenvatinib and pembrolizumab in 32 patients with previously treated advanced non–microsatellite instability-high (MSI-H)/mismatch repair proficient (pMMR) colorectal cancer (CRC).
Negative Prognosis Associated with KRAS Mutation Status in CRC May be Linked to Race/Ethnicity
Investigators reviewed data from 202,237 patients from the Surveillance, Epidemiology, and End Results (SEER) registry who had been diagnosed CRC with 2010 and 2015.
Clinical Score for Well-Differentiated NETs Under Consideration for PRRT Found to Predict PFS
Investigators developed a clinical score to address how to categorize patients with well-differentiated neuroendocrine tumors (NETs) who are being considered for peptide receptor radionuclide therapy (PRRT) and how to sequence therapy.
COBRA Study to Test ctDNA as Biomarker for Adjuvant Chemotherapy Benefit in Colon Cancer
COBRA investigators will evaluate circulating tumor DNA (ctDNA) as a biomarker for adjuvant chemotherapy benefit in 1408 patients with resected, stable stage IIA colon cancer.
Tivozanib and Durvalumab Doublet Regimen Is Well-Tolerated in HCC
Combination tivozanib and durvalumab was found to be well-tolerated in patients with advanced, treatment-naïve hepatocellular carcinoma (HCC).
Longer Maintenance of QoL in BRAF V600E-Mutant Metastatic Colorectal Cancer With Triplet Regimen vs an Irinotecan-Based Regimen
The randomized, phase 3 BEACON CRC trial was a 3-arm study conducted in patients with pretreated metastatic CRC characterized by a BRAF V600E mutation.
Phase 2 Results: Pembrolizumab Shows Antitumor Activity and a Manageable Safety Profile in Anal Squamous Cell Carcinoma
This single-arm, phase 2 study of pembrolizumab in advanced solid tumor cancers did not limit patient enrollment based on tumor PD-L1 expression level.
Primary Tumor Resection Prior to Chemotherapy Does Not Improve OS in Patients With Synchronous Metastatic CRC
Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis.
Older Adults Are Less Likely to Receive Second-Line Therapy for Metastatic Colorectal Cancer, Study Reports
Even though older adults were prescribed second-line therapies less frequently than younger adults, patients had similar overall survival outcomes across age subgroups.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO GI 2020
Loading... 
Loading...